Clinical trial
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With…
NCT00096200 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00096200 |
|---|---|
| Title | Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
| Official title | A Phase II Trial Of BAY 43-9006, A Novel Raf Kinase Inhibitor Plus Paclitaxel/Carboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma |
| Intervention type | Drug |
| Interventions | Carboplatin, Paclitaxel, Sorafenib Tosylate |
| Enrollment | 44 |
| Start date | Aug 1, 2004 |
| Primary completion | Apr 21, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Nov 9, 2004 |
| Last update posted | Feb 8, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: